Evidence map›Paper›PMID 38848870›Full record

SynthesisAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2024

A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology.

Jay A Lieberman, Derek K Chu, Tasnuva Ahmed, Timothy E Dribin, Elissa M Abrams, Aikaterini Anagnostou, Kimberly G Blumenthal, Mark Boguniewicz, Nicole M Chase, David B K Golden and 18 more

Erratum issuedAbstract readSystematic ReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Safety of biologics for the treatment of asthma in children and adolescents: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  4. MMR and varicella immunization during dupilumab therapy.The journal of allergy and clinical immunology. Global · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Innovations and Emerging Therapies in Atopic Dermatitis Part 1.Current treatment options in allergy · 2025
    Article
  11. Adverse effects of biologics used to treat asthma.Therapeutic advances in respiratory disease
    Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Jay A LiebermanDepartment of Pediatrics, The University of Tennessee Health Science Center and LeBonheur Children's Hospital, Memphis, Tennessee. Electronic address: jlieber1@uthsc.edu.
Derek K ChuDepartments of Medicine and Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada; Evidence in Allergy Group, McMaster University and The Research Institute of St. Joe's Hamilton, Hamilton, Canada.
Tasnuva AhmedDepartment of Health Research Methods, Evidence, and Impact, Evidence in Allergy Group, McMaster University, Hamilton, Canada.
Timothy E DribinDivision of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Elissa M AbramsDepartment of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, Canada.
Aikaterini AnagnostouSection of Immunology, Allergy and Retrovirology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
Kimberly G BlumenthalDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Mark BoguniewiczDivision of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colorado.
Nicole M ChaseDivision of Pulmonary, Allergy, Critical Care, and Sleep, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota.
David B K GoldenDivision of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nicholas L HartogDepartment of Allergy and Immunology, Corewell Health Helen DeVos Children's Hospital, Michigan State University College of Human Medicine, Grand Rapids, Michigan.
Jennifer R HeimallDivision of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Tina HoDermatology Section, Division of Immunology, Boston Children's Hospital and Harvard Medical school, Boston, Massachusetts.
Monica G LawrenceDepartments of Medicine and Pediatrics, University of Virginia, Charlottesville, Virginia.
David A KhanDivision of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Timothy Dean MinniearDivision of Pediatric Infectious Diseases, University of Tennessee Health Science Center, Memphis, Tennessee.
S Shahzad MustafaDivision of Allergy, Immunology, and Rheumatology, Department of Medicine, Rochester Regional Health and the University of Rochester School of Medicine and Dentistry, Rochester, New York.
John J OppenheimerRutgers New Jersey Medical School, Newark, New Jersey.
Elizabeth J PhillipsCenter for Drug Safety and Immunology, Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Allison RamseyDivision of Allergy, Immunology, and Rheumatology, Department of Medicine, Rochester Regional Health and the University of Rochester School of Medicine and Dentistry, Rochester, New York.
Nicholas L RiderSection of Allergy & Immunology, Department of Health Systems & Implementation Science, The Carilion Clinic, Virginia Tech Carilion School of Medicine, Roanoke, Virginia.
Lynda SchneiderDivision of Immunology, Boston Children's Hospital, Boston, Massachusetts.
Marcus S ShakerSection of Allergy and Clinical Immunology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Jonathan M SpergelDivision of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Cosby A StoneDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
David R StukusDivision of Allergy/Immunology, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio.
Julie WangDivision of Allergy & Immunology, Department of Pediatrics, Icahn School of Medicine, Mount Sinai, New York.
Matthew J GreenhawtSection of Allergy & Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
Clinical Informatics to Advance Epidemiology and Pharmacogenetics of Serious Cutaneous Adverse Drug ReactionsR01AI150295 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHOU, LI · 2019 to 2022
$2.8M
Improving Equitable Access to Penicillin Allergy De-LabelingR01HS029319 · AHRQ · TUFTS MEDICAL CENTER · PI BLUMENTHAL, KIMBERLY G., WURCEL, ALYSSE GAIL · 2023 to 2025
$1.2M
Improving Anaphylaxis Outcomes Through Personalized Care StrategiesK23AI175525 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI Timothy Erick Dribin · 2024 to 2026
$577k
Use of NLP to Extract Risk Indicators for Immunologic Disease from the Text of EHRs (UNIITE)R21AI164100 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI RIDER, NICHOLAS L, ROBERTS, KIRK EDWARD · 2022 to 2024
$379k
AHRQ HHS R01 HS029319NCATS NIH HHS UL1 TR001425NIAID NIH HHS K23 AI175525NIAID NIH HHS R01 AI150295NIAID NIH HHS R21 AI164100
6 · The paper itself

Abstract

backgroundDupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor alpha subunit, thus blocking the effects of IL-4 and IL-13, and has shown efficacy in treating various conditions including asthma, atopic dermatitis, eosinophilic esophagitis, and others. Because of its immune modulatory effects, clinical trials that studied dupilumab did not allow patients to receive live vaccines during the clinical trials because of an abundance of caution, and thus package inserts recommend that patients who are being treated with dupilumab should avoid live vaccines. Because dupilumab is now approved for use in patients from 6 months of age for the treatment of atopic dermatitis, this reported contraindication is now posing a clinical dilemma for patients and clinicians.

objectiveTo perform a systematic review of literature on the safety and efficacy of vaccinations in patients who are receiving dupilumab and to provide expert guidance on the use of vaccines in patients who are receiving dupilumab.

methodsA systematic review of the literature was performed, and an expert Delphi Panel was assembled.

resultsThe available literature on patients who received vaccinations while using dupilumab overall suggests that live vaccines are safe and that the vaccine efficacy, in general, is not affected by dupilumab. The expert Delphi panel agreed that the use of vaccines in patients receiving dupilumab was likely safe and effective.

conclusionVaccines (including live vaccines) can be administered to patients receiving dupilumab in a shared decision-making capacity.

Indexed as

Antibodies, Monoclonal, HumanizedVaccinesAsthmaDelphi TechniqueDermatitis, AtopicHumansVaccinationAntibodies, Monoclonal, HumanizeddupilumabVaccines

Identifiers

PMID38848870
PMCPMC11459655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.